Loading cancer entity…
Loading cancer entity…
Clinical trials
792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003624 | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | terminated | Phase 2 | — | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2013 | clinicaltrials |
| NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | completed | Phase 2 | 68 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 4, 2013 | clinicaltrials |
| NCT01661868 |
| Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer |
| withdrawn |
| Phase 2 |
| 0 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Aug 21, 2012 |
| clinicaltrials |
| NCT00501644 | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00085384 | PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | terminated | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00445549 | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 26, 2012 | clinicaltrials |
| NCT00032162 | Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer | completed | Phase 1 / Phase 2 | 63 | AGO Study GroupOTHER | 1 | May 31, 2012 | clinicaltrials |
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00004060 | Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | — | Daiichi SankyoINDUSTRY | 1 | May 16, 2012 | clinicaltrials |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 18, 2012 | clinicaltrials |
| NCT00035100 | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | completed | Phase 2 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 16, 2012 | clinicaltrials |
| NCT01570582 | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | unknown | Phase 2 | 314 | Korean Gynecologic Oncology GroupOTHER | 1 | Apr 4, 2012 | clinicaltrials |
| NCT00466986 | Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 40 | Southeastern Gynecologic OncologyOTHER | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00003160 | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | unknown | Phase 2 | 100 | TheradexINDUSTRY | 1 | Apr 20, 2011 | clinicaltrials |
| NCT00189566 | Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | completed | Phase 2 | 165 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00517621 | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | completed | Phase 2 | 100 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00217529 | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00217555 | Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00063401 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 8, 2010 | clinicaltrials |
| NCT00905658 | Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer | unknown | Phase 2 | 120 | Centre Oscar LambretOTHER | 1 | Jul 29, 2009 | clinicaltrials |
| NCT00157560 | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma | completed | Phase 2 | 83 | Massachusetts General HospitalOTHER | 1 | Jan 3, 2008 | clinicaltrials |
| NCT00074867 | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer | completed | Phase 2 | 29 | PfizerINDUSTRY | 2 | Nov 7, 2006 | clinicaltrials |
| NCT00103545 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | completed | Phase 1 / Phase 2 | 36 | AGO Study GroupOTHER | 1 | Oct 2, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Apr 11, 2013source: clinicaltrials